SCHEMBL2409162

SCHEMBL2409162

CCCOc1ccc(I)nc1OCc1ccc(OC)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APP P05067 7/20 0.48
CNR1 P21554 2/20 0.41
CNR2 P34972 2/20 0.41
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
MAOB P27338 1/20 0.40
HTR1A P08908 1/20 0.39
ADRA1D P25100 1/20 0.39
ADRA1A P35348 1/20 0.39
ADRA1B P35368 1/20 0.39
HRH4 Q9H3N8 1/20 0.39
IDO1 P14902 1/20 0.38
AGXT P21549 1/20 0.38
NTRK1 P04629 1/20 0.38
CSF1R P07333 1/20 0.38
NTRK3 Q16288 1/20 0.38
NTRK2 Q16620 1/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
PDE2A O00408 1/20 0.38
LMNA P02545 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2414177 0.87 APP (0.54) APPCNR1CNR2NPC1RAB9A
SCHEMBL23167115 0.86 APP (0.50) APPCNR1CNR2NPC1RAB9A
SCHEMBL2433879 0.85 ABCB1 (0.53) APPCNR1CNR2NPC1RAB9A
SCHEMBL2413783 0.84 APP (0.54) APPCNR1CNR2NPC1RAB9A
SCHEMBL2416615 0.81 APP (0.48) APPCNR1CNR2NPC1RAB9A
SCHEMBL2418124 0.80 APP (0.47) APPCNR1CNR2NPC1RAB9A
SCHEMBL2908833 0.79 FPR2 (0.41) APPNPC1RAB9ASMN1; SMN2HTT
SCHEMBL14478707 0.79 APP (0.54) APPCNR1CNR2NPC1RAB9A
SCHEMBL22588382 0.78 APP (0.54) APPNPC1RAB9AMAOBSMN1; SMN2
SCHEMBL15614391 0.78 CYP2C9 (0.41) CNR1CNR2SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8822503-B2 2-pyridone compounds TAISHO PHARMACEUTICAL CO., LTD (JP) 2014-09-02 US disclosed
US-8822503-B2 2-pyridone compounds TAISHO PHARMACEUTICAL CO., LTD (JP) 2014-09-02 US disclosed
US-8822503-B2 2-pyridone compounds TAISHO PHARMACEUTICAL CO., LTD (JP) 2014-09-02 US disclosed
EP-2508513-A1 2-PYRIDONE COMPOUNDS Taisho Pharmaceutical Co., Ltd. (JP) 2012-10-10 EP disclosed
EP-2508513-A1 2-PYRIDONE COMPOUNDS Taisho Pharmaceutical Co., Ltd. (JP) 2012-10-10 EP disclosed
US-20110237791-A1 2-PYRIDONE COMPOUNDS TAISHO PHARMACEUTICAL CO., LTD (JP) 2011-09-29 US disclosed
WO-2011068211-A1 2-PYRIDONE COMPOUNDS 大正製薬株式会社 (JP) 2011-06-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110237791-A1 2-PYRIDONE COMPOUNDS PDXK, HK1, KCNJ2 APP 2520/4885CNR1 985/4885CNR2 825/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.